A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Fidanacogene-elaparvovec (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Sponsors Spark Therapeutics
- 16 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 03 Dec 2016 Results published in the Media Release
- 19 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.